Institutional members access full text with Ovid®

Share this article on:

Rotavirus Vaccination in Central Europe

Mészner, Zsófia*; Anca, Ioana; André, Francis; Chlibek, Roman§; Čižman, Milan||; Grzesiowski, Paweł; Mangarov, Atanas#; Pokorn, Marko||; Prymula, Roman**; Richter, Darko††; Salman, Nuran‡‡; Šimurka, Pavol§§; Tamm, Eda||||; Tešović, Goran¶¶; Urbancikova, Ingrid##; Usonis, Vytautas***; Zavadska, Dace†††; on Behalf of the Central European Vaccine Awareness Group (CEVAG)

Journal of Pediatric Gastroenterology & Nutrition: June 2013 - Volume 56 - Issue 6 - p 586–596
doi: 10.1097/MPG.0b013e31828dc35d
Position Paper

ABSTRACT: Each year, rotavirus (RV) infection is the leading cause of acute gastroenteritis requiring hospitalisation and of nosocomially transmitted diseases in children younger than 5 years across Central European Vaccination Awareness Group (CEVAG) countries; however, inadequate surveillance systems and lack of routine RV testing still exist in most CEVAG countries, making it difficult to accurately assess the present burden of acute RV gastroenteritis in the younger population. Furthermore, routine immunisation of infants with RV vaccines has not been implemented, and no official and uniform recommendations exist in most of the countries in these territories. The present study provides CEVAG country-specific estimates of the disease burden of RV gastroenteritis among the youngest population and presents evidence-based advice on the use of RV vaccines in the region, while providing a framework for vaccination at the national level.

*National Institute of Child Health, Budapest, Hungary

University of Medicine and Pharmacy “Carol Davila” Bucharest, Institute for Mother and Child Care, Bucharest, Romania

Chaussée de Huy, Chaumont-Gistoux, Belgium

§Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic

||Department of Infectious Diseases, University Medical Centre, Ljubljana, Slovenia

Foundation for the Infection Prevention Institute, Warsaw, Poland

#Infectious Diseases Hospital, Sofia, Bulgaria

**University Hospital, Hradec Kralove, Czech Republic

††Department of Pediatrics, University Hospital Center, Zagreb, Croatia

‡‡Division of Infectious Disease and Clinical Microbiology, University of Istanbul, Istanbul, Turkey

§§University of Trenčín, Pediatric Clinic, Faculty Hospital, Trenčín, Slovakia

||||Children's Clinic of Tartu University Hospital, Tartu, Estonia

¶¶Paediatric Infectious Diseases Department, University of Zagreb, School of Medicine, Zagreb, Croatia

##Department of Paediatric Infectious Diseases, Children's Faculty Hospital, Košice, Slovakia

***Vilnius University Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

†††Department of Pediatrics, Riga Stradins University, Riga, Latvia.

Address correspondence and reprint requests to Professor Zsófia Mészner, MD, National Institute of Child Health, Budapest, Hungary (e-mail: zsmeszner@ogyei.hu).

Received 11 October, 2012

Accepted 13 February, 2013

Preparation of this report was supported by an educational grant from GlaxoSmithKline and editorial assistance was provided by Wells Healthcare Communications Ltd.

Z.M. is a consultant to Wyeth, GlaxoSmithKline (GSK), MSD, Sanofi Pasteur, Novartis and Baxter on vaccination issues and has also received travel grants. I.A. has been the principal investigator in clinical studies supported by GSK, Apogepha, and Ferring. She has also been a scientific consultant to GSK, Wyeth Lederle, Teva, AstraZeneca, and Nestlé, and has received sponsorship from GSK, Wyeth, and Nestlé to attend scientific meetings. R.C. has been the principal investigator in clinical studies supported by GSK and Novartis. He has also been a scientific consultant to Baxter, GSK, Novartis, Aventis Pasteur, and Pfizer and received sponsorship from GSK and Aventis Pasteur to attend scientific meetings. M.C. is a member of GSK advisory boards on vaccines and has received honoraria for lectures on vaccine use from GSK, Pfizer, and MSD. P.G. as a lecturer has received fees for lectures, workshops, and scientific meetings from Baxter, GSK, Novartis, MSD, Aventis Pasteur, Pfizer, Wyeth, and Solvay. A.M. has been a scientific consultant to Wyeth, GSK, Aventis Pasteur, Pfizer, Danone, and Solvay Pharma and has received sponsorship from these companies to attend scientific meetings. M.P. has received lecture fees from GSK Slovenia, speaker fees from GSK, and has received sponsorship from GSK and PharmaSwiss Slovenia to attend scientific meetings. R.P. received honoraria and research grants from GSK and honoraria from MSD. D.R. has received honoraria for lectures on vaccines and respiratory drugs from GSK Croatia, MSD Idea Inc, Croatia, Pfizer, and Medoka (representing Sanofi Pasteur). P.S. has received consulting and lecture fees and received sponsorship to attend scientific meetings from GSK, Pfizer, and MSD. E.T. has received sponsorship from GSK and PharmaSwiss to attend scientific meetings. G.T. has received sponsorship from GSK, MSD, and Wyeth to attend scientific meetings. I.U. has been a scientific consultant to GSK and Pfizer and has received lecture fees from GSK, Pfizer, MSD, and Novartis, and has received sponsorship from GSK, Pfizer, and Sanofi Pasteur to attend scientific meetings. V.U. has been the principal investigator in clinical studies supported by GSK, Novartis, and Pfizer. He has also been a scientific consultant to Aventis Pasteur, Baxter, GSK, Merck, and Pfizer, and has received sponsorship from these companies to attend scientific meetings. D.Z. has received lecture fees from GSK, Sanofi Pasteur, and Abbott and has received sponsorship from GSK to attend scientific meetings. F.A. and N.S. have no competing interests.

Copyright 2013 by ESPGHAN and NASPGHAN